Pembrolizumab plus BCG after tumor removal in upper urinary tract
Part of Cancer, Kidney & urinary clinical trials.
This trial studies pembrolizumab (an immune therapy) given with BCG (a treatment placed into the urinary tract) after your upper urinary tract tumor has been fully ablated. It is for people who have high-grade disease and either cannot or do not want radical kidney/ureter removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign consent forms.
- You have high-grade cancer or pre-cancer in the upper urinary tract (CIS, Ta, or T1) that can be fully destroyed with ureteroscopy or a similar procedure.
- You are not willing or not medically able to have radical nephroureterectomy (major surgery removing the kidney/ureter).
- You can provide recent tumor tissue from your newest upper urinary tract biopsy or sample.
- Your overall health is good enough (ECOG performance status 0–1) and your blood/organ tests are acceptable within 28 days before treatment.
- You can follow pregnancy prevention rules (and for most participants, use contraception during treatment and for 120 days after the last dose).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial tests if a special type of tumor removal (ERBT) followed by BCG immunotherapy is better than standard treatment for medium- or high-risk non-muscle-invasive bladder cancer. It may help people whose bladder cancer has come back, has multiple tumors, or has a tumor larger than 1 cm.
This trial studies pembrolizumab (an immunotherapy) in people with muscle-invasive bladder cancer who had a combined “trimodality” treatment and then achieved a complete response. The goal is to help control the cancer after the initial treatment is finished.
This trial tests whether a specific schedule of BCG (a weakened germ that boosts the immune system) placed directly into the bladder is safe and effective for medium- to high-risk bladder cancer that hasn't grown into the muscle. It aims to see if adjusting the standard BCG course can work better for people with a PD-L1-positive tumor.
Hear when a new High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.